<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: risks associated", fill: "#08457e"},
{source: "2: risks associated", target: "2: operations", fill: "#08457e"},
{source: "2: operations", target: "2: Manufacturing and Quality Control ", fill: "#08457e"},
{source: "2: Manufacturing and Quality Control ", target: "2: following risk factors should", fill: "#08457e"},
{source: "2: following risk factors should", target: "2: carefully", fill: "#08457e"},
{source: "2: risks associated", target: "3: injury from", fill: "#b22222"},
{source: "3: injury from", target: "3: Dexatrim ", fill: "#b22222"},
{source: "3: Dexatrim ", target: "3: products containing ephedrine which", fill: "#b22222"},
{source: "3: products containing ephedrine which", target: "3: discontinued manufacturing", fill: "#b22222"},
{source: "3: discontinued manufacturing", target: "3: September ", fill: "#b22222"},
{source: "3: injury from", target: "9: product liability coverage", fill: "#00b7eb"},
{source: "9: product liability coverage", target: "9: injury from", fill: "#00b7eb"},
{source: "9: injury from", target: "9: Dexatrim ", fill: "#00b7eb"},
{source: "9: Dexatrim ", target: "9: coverage through", fill: "#00b7eb"},
{source: "9: coverage through", target: "9: captive insurance", fill: "#00b7eb"},
{source: "9: captive insurance", target: "9: February ", fill: "#00b7eb"},
{source: "9: February ", target: "9: excess coverage through third party", fill: "#00b7eb"},
{source: "9: product liability coverage", target: "10: significant", fill: "#c74375"},
{source: "10: significant", target: "10: liabilities", fill: "#c74375"},
{source: "10: liabilities", target: "10: to the Dexatrim ", fill: "#c74375"},
{source: "10: to the Dexatrim ", target: "10: products which", fill: "#c74375"},
{source: "10: products which", target: "10: product liability insurance", fill: "#c74375"},
{source: "10: product liability insurance", target: "10: sufficient resources", fill: "#c74375"},
{source: "10: sufficient resources", target: "10: insurance coverage", fill: "#c74375"},
{source: "10: significant", target: "15: liability", fill: "#fad6a5"},
{source: "15: liability", target: "15: captive insurance", fill: "#fad6a5"},
{source: "15: captive insurance", target: "15: third party insurers", fill: "#fad6a5"},
{source: "15: third party insurers", target: "15: provides coverage", fill: "#fad6a5"},
{source: "15: liability", target: "38: advertising", fill: "#0bda51"},
{source: "38: advertising", target: "38: complicated federal", fill: "#0bda51"},
{source: "38: complicated federal", target: "38: governmental", fill: "#0bda51"},
{source: "38: governmental", target: "38: regulations", fill: "#0bda51"},
{source: "38: advertising", target: "52: cannot assure", fill: "#674c47"},
{source: "52: cannot assure", target: "52: products will contribute favorably", fill: "#674c47"},
{source: "52: cannot assure", target: "147: shareholder rights", fill: "#3cd070"},
{source: "147: shareholder rights", target: "147: restated charter contain provisions", fill: "#3cd070"},
{source: "147: restated charter contain provisions", target: "147: merger tender offer", fill: "#3cd070"},
{source: "147: shareholder rights", target: "START_HERE", fill: "#3cd070"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Diversified Financial Services</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accuse</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Chattem">Chattem</a></td>
      <td>Chattem, Inc. is an American, Chattanooga, Tennessee-based, producer and marketer of over-the-counter healthcare products, toiletries, dietary supplements, topical analgesics, and medicated skin care products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Marion_Merrell_Dow">Marion Merrell Dow</a></td>
      <td>Marion Merrell Dow and its predecessor Marion Laboratories was a U.S. pharmaceutical company based in Kansas City, Missouri from 1950 until 1996.\nThe company specialized in bringing to market drugs that had been discovered but unmarketed by other companies including Cardizem which treats arrhythmias and high blood pressure, Carafate (an ulcer treatment), Gaviscon (an antacid), Seldane (a withdrawn antihistamine), Nicorette (anti-smoking gum) and Cepacol mouthwash.The company operating out of its headquarters at 9300 Ward Parkway was a springboard for its founder Ewing Marion Kauffman to start the Kansas City Royals baseball team.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Paul_Hudson_(businessman)">Paul Hudson (businessman)</a></td>
      <td>Paul Hudson (born 14 October 1967) is a British businessman, and the chief executive (CEO) of Sanofi, the world's fifth largest pharmaceutical company by prescription drug sales.\n\n\n== Early life ==\nHudson earned a degree in economics from Manchester Metropolitan University, and a diploma in marketing from the Chartered Institute of Marketing.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Brainiac_(band)">Brainiac (band)</a></td>
      <td>Brainiac (sometimes stylized as 3RA1N1AC) was an American indie rock band formed in 1992, and disbanded after the sudden death of lead singer Tim Taylor in 1997.\n\n\n== Biography ==\nBrainiac was formed in Dayton, Ohio, United States in January 1992 with vocalist, guitarist and keyboard player (particularly Moog synthesizers) Tim Taylor (July 20, 1968 – May 23, 1997), bassist Monostereo (Juan Monasterio), guitarist Michelle Bodine and drummer Tyler Trent.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_withdrawn_drugs">List of withdrawn drugs</a></td>
      <td>Drugs or medicines may be withdrawn from commercial markets because of risks to patients, but also because of commercial reasons (e.g. lack of demand and relatively high production costs).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Genzyme">Genzyme</a></td>
      <td>Genzyme was an American biotechnology company based in Cambridge, Massachusetts. Since its acquisition in 2011, Genzyme (also known as Genzyme Transgenics Corp or GTC Biotherapeutics) has been a fully owned subsidiary of Sanofi.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Liability_insurance">Liability insurance</a></td>
      <td>Liability insurance (also called third-party insurance) is a part of the general insurance system of risk financing to protect the purchaser (the "insured") from the risks of liabilities imposed by lawsuits and similar claims and protects the insured if the purchaser is sued for claims that come within the coverage of the insurance policy.\nOriginally, individual companies that faced a common peril formed a group and created a self-help fund out of which to pay compensation should any member incur loss (in other words, a mutual insurance arrangement).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_other">Significant other</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bit_numbering">Bit numbering</a></td>
      <td>In computing, bit numbering is the convention used to identify the bit positions in a binary number.\n\n\n== Bit significance and indexing ==\n\nIn computing, the least significant bit (LSB) is the bit position in a binary integer representing the binary 1s place of the integer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_form">Significant form</a></td>
      <td>Significant form refers to an aesthetic theory developed by English art critic Clive Bell which specified a set of criteria for what qualified as a work of art.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Others">Significant Others</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Statistical_significance">Statistical significance</a></td>
      <td>In statistical hypothesis testing, a result has statistical significance when it is very unlikely to have occurred given the null hypothesis. More precisely, a study's defined significance level, denoted by \n  \n    \n      \n        α\n      \n    \n    {\displaystyle \alpha }\n  , is the probability of the study rejecting the null hypothesis, given that the null hypothesis is true; and the p-value of a result, \n  \n    \n      \n        p\n      \n    \n    {\displaystyle p}\n  , is the probability of obtaining a result at least as extreme, given that the null hypothesis is true.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Liability_(financial_accounting)">Liability (financial accounting)</a></td>
      <td>In financial accounting, a liability is defined as the future sacrifices of economic benefits that the entity is\nobliged to make to other entities as a result of past transactions or other past events, the settlement of which may result in the transfer or use of assets, provision of services or other yielding of economic benefits in the future.\n\n\n== Characteristics ==\nA liability is defined by the following characteristics:\n\nAny type of borrowing from persons or banks for improving a business or personal income that is payable during short or long time;\nA duty or responsibility to others that entails settlement by future transfer or use of assets, provision of services, or other transaction yielding an economic benefit, at a specified or determinable date, on occurrence of a specified event, or on demand;\nA duty or responsibility that obligates the entity to another, leaving it little or no discretion to avoid settlement; and,\nA transaction or event obligating the entity that has already occurredLiabilities in financial accounting need not be legally enforceable; but can be based on equitable obligations or constructive obligations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Limited_liability_company">Limited liability company</a></td>
      <td>A limited liability company (LLC) is the US-specific form of a private limited company. It is a business structure that can combine the pass-through taxation of a partnership or sole proprietorship with the limited liability of a corporation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Legal_liability">Legal liability</a></td>
      <td>In law, liable means  "responsible or answerable in law; legally obligated". Legal liability concerns both civil law and criminal law and can arise from various areas of law, such as contracts, torts, taxes, or fines given by government agencies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Limited_liability">Limited liability</a></td>
      <td>Limited liability is a legal status where a person's financial liability is limited to a fixed sum, most commonly the value of a person's investment in a corporation, company or partnership. If a company that provides limited liability to its investors is sued, then the claimants are generally entitled to collect only against the assets of the company, not the assets of its shareholders or other investors.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/No_liability">No liability</a></td>
      <td>A no-liability company in Australia (suffix NL) is a company which, under the Corporations Act 2001 (Cth), must have as its stated objects that it is solely a mining company and that it is not entitled to calls on the unpaid issue price of shares. It is a company which is restricted to mining activities and is the only sort of corporation which is entitled to this form of liability, given the sometimes financially risky business of mining.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Limited_liability_partnership">Limited liability partnership</a></td>
      <td>A limited liability partnership (LLP) is a partnership in which some or all partners (depending on the jurisdiction) have limited liabilities. It therefore can exhibit elements of partnerships and corporations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_(European_Union)">Regulation (European Union)</a></td>
      <td>A regulation is a legal act of the European Union that becomes immediately enforceable as law in all member states simultaneously. Regulations can be distinguished from directives which, at least in principle, need to be transposed into national law.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Formula_One_regulations">Formula One regulations</a></td>
      <td>The numerous Formula One regulations, made and enforced by the FIA and later the FISA, have changed dramatically since the first Formula One World Championship in 1950. This article covers the current state of F1 technical and sporting regulations, as well as the history of the technical regulations since 1950.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Radio_regulation">Radio regulation</a></td>
      <td>Radio regulation refers to the regulation and licensing of radio in international law, by individual governments, and by municipalities.\n\n\n== International regulation ==\nThe International Telecommunication Union (ITU) is a specialized agency of the United Nations (UN) that is responsible for issues that concern information and communication technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Queen's_Regulations">Queen's Regulations</a></td>
      <td>The Queen's Regulations (first published in 1731 and known as the King's Regulations when the monarch is a king) is a collection of orders and regulations in force in the Royal Navy, British Army, Royal Air Force, and Commonwealth Realm Forces (where the same person as on the British throne is also their separate head of state), forming guidance for officers of these armed services in all matters of discipline and personal conduct. Originally, a single set of regulations were published in one volume.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Alisher_Usmanov">Alisher Usmanov</a></td>
      <td>Alisher Burkhanovich Usmanov (Russian: Алишер Бурханович Усманов; born 9 September 1953) is an Uzbek-born Russian businessman and oligarch. By 2022, Usmanov had an estimated net worth of $19.5 billion and was among the world's 100 wealthiest people.Usmanov made his wealth after the collapse of the Soviet Union, through metal and mining operations, and investments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2011_military_intervention_in_Libya">2011 military intervention in Libya</a></td>
      <td>On 19 March 2011, a multi-state NATO-led coalition began a military intervention in Libya, to implement United Nations Security Council Resolution 1973, in response to events during the First Libyan Civil War. With ten votes in favour and five abstentions, the UN Security Council's intent was to have "an immediate ceasefire in Libya, including an end to the current attacks against civilians, which it said might constitute "crimes against humanity" ...</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hardware_random_number_generator">Hardware random number generator</a></td>
      <td>In computing, a hardware random number generator (HRNG) or true random number generator (TRNG) is a device that generates random numbers from a physical process, rather than by means of an algorithm.  Such devices are often based on microscopic phenomena that generate low-level, statistically random "noise" signals, such as thermal noise, the photoelectric effect, involving a beam splitter, and other quantum phenomena.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tourism_in_Abkhazia">Tourism in Abkhazia</a></td>
      <td>Tourism in Abkhazia is possible under Georgian law for foreigners entering the occupied territory from Georgia, although Georgia cannot assure the safety inside disputed territory.\nHowever, the Abkazian beaches on the Black Sea continue to be accessible for tourists coming from the Russian side of the Abkhazia–Russia border which is not under Georgian control.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medical_license">Medical license</a></td>
      <td>A medical license is an occupational license that permits a person to legally practice medicine. In most countries, a person must have a medical license bestowed either by a specified government-approved professional association or a government agency before he or she can practice medicine.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Some of the <font color="blue">risks associated</font>     with  our  <font color="blue">operations</font>  are  described in the “Competition,”“Government     Regulation,”“Environmental,”  and  “Manufacturing and Quality Control”     portions of this Form 10-K In addition to the other information contained     in  this  Form  10-K,  the  <font color="blue">following risk factors should</font> be <font color="blue">carefully</font>     considered</td>
    </tr>
    <tr>
      <td>We may face <font color="blue"><font color="blue">additional</font> lawsuits</font> alleging <font color="blue">injury from</font> the use of <font color="blue"><font color="blue">Dexatrim </font>    </font>products <font color="blue">containing ephedrine</font>, which we <font color="blue"><font color="blue"><font color="blue">discontinue</font>d</font> <font color="blue">manufacturing</font></font> and     shipping in <font color="blue">September </font>2002, or from other products that we currently produce     or may produce in the future</td>
    </tr>
    <tr>
      <td>We are <font color="blue">currently named as</font> a <font color="blue">defendant</font> in <font color="blue">two lawsuits</font> alleging that the     plaintiffs were <font color="blue">injured as</font> a result of the ingestion of <font color="blue">Dexatrim </font>containing     ephedrine</td>
    </tr>
    <tr>
      <td><font color="blue">On <font color="blue">December </font></font>30, 2003, the FDA issued a <font color="blue">consumer alert on</font> the     safety of <font color="blue"><font color="blue"><font color="blue">dietary <font color="blue">supplements</font></font> <font color="blue">containing ephedrine</font></font> <font color="blue">alkaloids</font></font> and on <font color="blue"><font color="blue">February </font>    </font>6, 2004 published a <font color="blue">final rule with respect</font> to these products</td>
    </tr>
    <tr>
      <td>The final     rule  prohibits  the  sale of <font color="blue"><font color="blue">dietary <font color="blue">supplements</font></font> <font color="blue">containing ephedrine</font></font>     <font color="blue">alkaloids</font> because <font color="blue">such <font color="blue">supplements</font> present</font> an <font color="blue">unreasonable risk</font> of illness     or injury</td>
    </tr>
    <tr>
      <td>The <font color="blue">final rule <font color="blue">became effective on</font></font> April 11, 2004</td>
    </tr>
    <tr>
      <td>Although we     <font color="blue"><font color="blue">discontinue</font>d</font> the <font color="blue">manufacturing</font> and shipment of <font color="blue">Dexatrim </font><font color="blue">containing ephedrine</font>     in <font color="blue">September </font>2002, the FDA’s <font color="blue">final rule may</font> result in <font color="blue"><font color="blue">additional</font> lawsuits</font>     being <font color="blue">filed against us</font> alleging damages related to the use or purchase of     <font color="blue">Dexatrim </font><font color="blue">containing ephedrine</font></td>
    </tr>
    <tr>
      <td>Our  available  <font color="blue"><font color="blue">product <font color="blue">liability</font></font> coverage</font> for the defense of lawsuits     alleging <font color="blue">injury from</font> the use of <font color="blue">Dexatrim </font>products <font color="blue">containing ephedrine</font>, or     from other products that we currently produce or may produce in the future,     consists  of  dlra20dtta0  million of <font color="blue">coverage through</font> our <font color="blue">captive insurance</font>     subsidiary, of which <font color="blue">approximately</font> dlra5dtta5 million is funded as of <font color="blue">February </font>17,     2006, and an <font color="blue">additional</font> dlra30dtta0 million of excess <font color="blue">coverage through</font> <font color="blue">third party</font>     insurers</td>
    </tr>
    <tr>
      <td>In the future, if we face <font color="blue">significant</font> <font color="blue">li<font color="blue">abilities</font></font> relating to the     <font color="blue">Dexatrim </font><font color="blue">products which</font> included ephedrine, our <font color="blue"><font color="blue">product <font color="blue">liability</font></font> insurance</font>     may be insufficient, and we may not have <font color="blue">sufficient resources</font> to satisfy     these <font color="blue">li<font color="blue">abilities</font></font> in excess of our <font color="blue">insurance coverage</font></td>
    </tr>
    <tr>
      <td>An <font color="blue">inherent risk</font> of our business is exposure to <font color="blue">product <font color="blue">liability</font></font> claims by     users of our products</td>
    </tr>
    <tr>
      <td>We may also experience <font color="blue">significant</font> <font color="blue">product <font color="blue">liability</font></font>     exposure related to our other products in the future</td>
    </tr>
    <tr>
      <td>Our  <font color="blue"><font color="blue">product <font color="blue">liability</font></font> insurance</font> coverage may be insufficient to cover     existing or future <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">inherently</font> makes us the <font color="blue">potential target</font> of <font color="blue">product <font color="blue">liability</font></font>     claims</td>
    </tr>
    <tr>
      <td>We have <font color="blue"><font color="blue">product <font color="blue">liability</font></font> insurance</font> through our <font color="blue">captive insurance</font>     subsidiary and <font color="blue"><font color="blue">third party</font> insurers</font> that <font color="blue">provides coverage</font> for product     <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">product <font color="blue">liability</font></font> insurance</font> coverage for all of our     products, including <font color="blue">Dexatrim </font>products <font color="blue">containing ephedrine</font>, consists of     dlra20dtta0 million of <font color="blue">coverage through</font> our <font color="blue">captive insurance</font> subsidiary, of which     <font color="blue">approximately</font>  dlra5dtta5  million is funded as of <font color="blue">February </font>17, 2006, and an     <font color="blue">additional</font> dlra30dtta0 million of excess <font color="blue">coverage through</font> <font color="blue"><font color="blue">third party</font> insurers</font></td>
    </tr>
    <tr>
      <td>All of our insurance policies are subject to certain <font color="blue">limitations</font> that are     <font color="blue">generally</font>  customary for policies of this type such as <font color="blue">deductibles</font> and     <font color="blue">exclusions</font> for exemplary and <font color="blue">punitive damages</font></td>
    </tr>
    <tr>
      <td>Since plaintiffs in product     <font color="blue">liability</font> claims may seek exemplary and <font color="blue">punitive damages</font>, if these damages     were awarded, some of our <font color="blue">insurance coverage</font> would not cover these amounts,     and we may not have <font color="blue">sufficient resources</font> to pay these damages</td>
    </tr>
    <tr>
      <td>Any amounts     paid by our insurance to satisfy product <font color="blue">li<font color="blue">abilities</font></font> would decrease product     <font color="blue">liability</font>  insurance  coverage  available for any other claims</td>
    </tr>
    <tr>
      <td>If our     <font color="blue">liability</font>  for  product  <font color="blue">liability</font> claims is <font color="blue">significant</font>, our existing     insurance is likely to be insufficient to cover these claims, and we may not     have <font color="blue">sufficient resources</font> to pay the <font color="blue">li<font color="blue">abilities</font></font> in excess of our insurance     coverage</td>
    </tr>
    <tr>
      <td>Furthermore, our <font color="blue"><font color="blue">product <font color="blue">liability</font></font> insurance</font> provided by third     <font color="blue">parties will</font> expire at the end of each annual policy period, currently in     May  of each year</td>
    </tr>
    <tr>
      <td>We may incur <font color="blue">significant</font> <font color="blue">additional</font> costs to obtain     <font color="blue">insurance coverage</font> upon the expiration of our <font color="blue">current policies</font> and may not     be able to obtain coverage in the future in amounts equal to that which we     currently have or in <font color="blue">amounts sufficient</font> to <font color="blue">satisfy future</font> claims</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">acquisition</font> strategy</font> is subject to risk and may not be successful</td>
    </tr>
    <tr>
      <td>A component of our <font color="blue">growth strategy depends on</font> our ability to <font color="blue">successfully</font>     execute <font color="blue">acquisition</font>s, which involves numerous risks including:     •   not <font color="blue">accurately</font> identifying <font color="blue">suitable products</font> or brands for <font color="blue">acquisition</font>;     •    <font color="blue"><font color="blue">difficult</font>ies</font>  in  <font color="blue">integrating</font>  the  <font color="blue">operations</font>,  <font color="blue">technologies</font> and     <font color="blue">manufacturing</font> processes of the acquired products;     •   the diversion of management’s attention from other business concerns;     and     •   incurring substantial <font color="blue"><font color="blue">additional</font> <font color="blue">indebtedness</font></font></td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________       Any  future  <font color="blue">acquisition</font>s,  or  potential  <font color="blue">acquisition</font>s, may result in     substantial costs, disrupt our <font color="blue">operations</font> or <font color="blue">materially <font color="blue">adversely</font> affect</font> our     operating results</td>
    </tr>
    <tr>
      <td>We face <font color="blue">significant</font> competition in the OTC health care, toiletries and     <font color="blue"><font color="blue">dietary <font color="blue">supplements</font></font> markets</font></td>
    </tr>
    <tr>
      <td>The OTC health care, toiletries and <font color="blue"><font color="blue">dietary <font color="blue">supplements</font></font> markets</font> are highly     <font color="blue">competitive</font>  and are <font color="blue">characterized by</font> the <font color="blue">frequent introduction</font> of new     products, including the migration of <font color="blue">prescription drugs</font> to the OTC market,     often  <font color="blue">accompanied by major <font color="blue">advertising</font></font> and <font color="blue">promotional support</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>introductions  <font color="blue">may <font color="blue">adversely</font> affect</font> our business <font color="blue">especially</font> because we     compete  in <font color="blue">categories</font> in <font color="blue">which product sales</font> are <font color="blue">highly influenced by</font>     <font color="blue">advertising</font> and promotions</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitor</font>s</font> include large <font color="blue">pharmaceutical</font>     <font color="blue">companies such as</font> Pfizer, Inc</td>
    </tr>
    <tr>
      <td>and Johnson &amp; Johnson, <font color="blue">consumer products</font>     <font color="blue">companies such as</font> Procter &amp; Gamble Co</td>
    </tr>
    <tr>
      <td>and <font color="blue"><font color="blue">dietary <font color="blue">supplements</font></font> companies</font>     such as Nature’s Bounty, Inc</td>
    </tr>
    <tr>
      <td>and Pharmaton Natural Health Products, many of     which have <font color="blue">considerably greater financial</font> and other <font color="blue">resources than</font> we do and     are not <font color="blue">as highly leveraged as</font> we are</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">competitor</font>s</font> are thus better     positioned to spend more on research and <font color="blue">development</font>, employ more <font color="blue">aggressive</font>     pricing strategies, utilize greater purchasing power, build stronger vendor     <font color="blue">relationships</font>  and  develop  <font color="blue">broader distribution channels than us</font></td>
    </tr>
    <tr>
      <td>In     addition, our <font color="blue"><font color="blue">competitor</font>s</font> have often been willing to use <font color="blue">aggressive</font> spending     <font color="blue">on trade promotions</font> and <font color="blue">advertising</font> as a strategy for <font color="blue">building market</font> share     at the expense of their <font color="blue"><font color="blue">competitor</font>s</font> including us</td>
    </tr>
    <tr>
      <td>The <font color="blue">private label</font> or     generic category has <font color="blue">also become <font color="blue">increasingly</font></font> more <font color="blue">competitive</font> in certain of     our <font color="blue">product markets</font></td>
    </tr>
    <tr>
      <td>If we are unable to continue to <font color="blue">introduce new</font> and     innovative  products that are attractive to consumers or are unable to     allocate <font color="blue">sufficient resources</font> to <font color="blue">effectively advertise</font> and promote our     products so that they achieve <font color="blue">wide spread market acceptance</font>, we may not be     able  to  <font color="blue">compete effectively</font>, and our operating results and financial     <font color="blue">condition may</font> be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Our  business  is  regulated  by  numerous  federal, state and foreign     <font color="blue"><font color="blue">government</font>al</font> authorities, which subjects us to <font color="blue">elevated compliance costs</font> and     risks of non-compliance</td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacturing</font>, <font color="blue">distributing</font>, processing, formulating, packaging and     <font color="blue">advertising</font> of our products are subject to numerous and <font color="blue">complicated federal</font>,     state  and  foreign  <font color="blue"><font color="blue">government</font>al</font>  <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with these     <font color="blue">regulations</font> is <font color="blue">difficult</font> and expensive</td>
    </tr>
    <tr>
      <td>In particular, the FDA regulates the     safety,  <font color="blue">manufacturing</font>, labeling and <font color="blue">distributing</font> of our OTC products,     <font color="blue">medical devices</font>, and <font color="blue">dietary <font color="blue">supplements</font></font></td>
    </tr>
    <tr>
      <td>In addition, the FTC <font color="blue">may regulate</font>     the  promotion  and <font color="blue">advertising</font> of our drug products, particularly OTC     versions and <font color="blue">dietary <font color="blue">supplements</font></font></td>
    </tr>
    <tr>
      <td>The EPA regulates our Bullfrog Mosquito     Coast <font color="blue">insect repellent products</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">also <font color="blue">regulated by</font> various</font> state     statutes, including the California Safe Drinking Water and Toxic Enforcement     Act of 1986</td>
    </tr>
    <tr>
      <td>If we fail to adhere to the standards required by these federal     and  state  <font color="blue">regulations</font>,  or are alleged to have failed to <font color="blue">adhere such</font>     <font color="blue">regulations</font>, our operating results and financial <font color="blue">condition may</font> be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends on</font> our ability to anticipate and respond in a timely     manner to changing <font color="blue">consumer demands</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends on</font> our products’ appeal to a <font color="blue">broad range</font> of consumers     <font color="blue">whose <font color="blue">preferences</font> cannot</font> be <font color="blue">predicted with certainty</font> and are subject to     change</td>
    </tr>
    <tr>
      <td>If our <font color="blue">current products</font> do not meet <font color="blue">consumer demands</font>, our sales may     decline</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">growth depends upon</font> our ability to develop new     <font color="blue">products through <font color="blue">product line</font> <font color="blue">extensions</font></font> and product modifications, which     <font color="blue">involve numerous risks</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">accurately</font> identify consumer     <font color="blue">preferences</font> and translate our knowledge into customer-accepted products or     <font color="blue">successfully</font> integrate these <font color="blue">products with</font> our <font color="blue">existing product platform</font> or     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may also experience <font color="blue">increased expenses incurred</font> in <font color="blue">connection</font>     with  product  <font color="blue">development</font>,  marketing  and  <font color="blue">advertising</font>  that are not     <font color="blue">subsequently</font>  supported  by  a  <font color="blue">sufficient level</font> of sales, <font color="blue">which would</font>     <font color="blue">negatively affect</font> our margins</td>
    </tr>
    <tr>
      <td>Furthermore, product <font color="blue">development</font> may divert     management’s attention from other business concerns, which could cause sales     of  our  existing  products to suffer</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that newly     developed <font color="blue">products will contribute favorably</font> to our operating results</td>
    </tr>
    <tr>
      <td>We rely on a few large customers, particularly Wal-Mart Stores, Inc, for a     <font color="blue">significant</font> portion of our sales</td>
    </tr>
    <tr>
      <td>In fiscal 2005, Wal-Mart Stores, Inc</td>
    </tr>
    <tr>
      <td>represented <font color="blue">approximately</font> 36prca of our     <font color="blue">total revenues</font>, our ten largest customers represented <font color="blue">approximately</font> 70prca of     our <font color="blue">total revenues</font> and our 20 largest customers represented <font color="blue">approximately</font>     81prca of our <font color="blue">total revenues</font></td>
    </tr>
    <tr>
      <td><font color="blue">Consistent </font><font color="blue">with industry practice</font>, we do not     operate under a long-term written supply contract with Wal-Mart Stores, Inc</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">would materially suffer</font> if we     lost Wal-Mart Stores, Inc</td>
    </tr>
    <tr>
      <td>as a <font color="blue">continuing major customer</font> or if our business     with Wal-Mart Stores, Inc</td>
    </tr>
    <tr>
      <td><font color="blue">significant</font>ly decreases</td>
    </tr>
    <tr>
      <td>The loss of sales to any     other  large  customer  <font color="blue">could also materially</font> and <font color="blue">adversely</font> affect our     financial results</td>
    </tr>
    <tr>
      <td>We may be <font color="blue"><font color="blue">adversely</font> affected</font> by <font color="blue">fluctuations</font> in <font color="blue">buying decisions</font> of mass     merchandiser, drug and <font color="blue">food trade buyers</font> and the <font color="blue">trend toward retail trade</font>     <font color="blue">consolidation</font></td>
    </tr>
    <tr>
      <td>21       _________________________________________________________________       We sell our products to <font color="blue">mass merchandiser</font> and food and <font color="blue">drug retailers</font> in the     <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Consequently, our <font color="blue">total revenues</font> are <font color="blue">affected by <font color="blue">fluctuations</font></font>     in the <font color="blue">buying patterns</font> of these customers</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">fluctuations</font> may</font> result     from wholesale <font color="blue">buying decisions</font>, economic <font color="blue">conditions</font> and other factors</td>
    </tr>
    <tr>
      <td>In     addition,  with the growing trend towards retail <font color="blue">consolidation</font>, we are     <font color="blue">increasingly</font>  <font color="blue">dependent upon</font> a few leading retailers, such as Wal-Mart     Stores, Inc, <font color="blue">whose bargaining strength continues</font> to grow due to their size</td>
    </tr>
    <tr>
      <td>Such retailers have demanded, and <font color="blue">may continue</font> to demand, increased service     and  order <font color="blue">accommodations as well as price</font> and <font color="blue">incremental promotional</font>     <font color="blue">investment concessions</font></td>
    </tr>
    <tr>
      <td>We also may be <font color="blue">negatively affect</font>ed by changes in the     policies  of  our retail trade customers such as inventory destocking,     <font color="blue">limitations</font> on access to shelf space and other <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on <font color="blue">third party</font> <font color="blue">manufacture</font>rs</font> for a portion of our <font color="blue">product portfolio</font>     including <font color="blue">products under</font> our Gold Bond, Icy Hot, Selsun and <font color="blue">Dexatrim </font>brands</td>
    </tr>
    <tr>
      <td>We <font color="blue">use <font color="blue">third party</font> <font color="blue">manufacture</font>rs</font> to make products representing <font color="blue">approximately</font>     40prca of our fiscal 2005 <font color="blue">sales volume</font>, including our <font color="blue">Gold Bond </font>medicated     powders and <font color="blue">foot spray</font>, the Icy Hot patches and sleeves, Herpecin-L, and our     line of <font color="blue">dietary <font color="blue">supplements</font></font> including <font color="blue">Dexatrim </font>Max and, <font color="blue"><font color="blue">international</font>ly</font>, our     line <font color="blue">of Selsun </font><font color="blue">medicated dandruff shampoos</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">will also rely on <font color="blue">third party</font></font>     <font color="blue">manufacture</font>rs to <font color="blue">manufacture</font> our Icy Hot Pro-Therapy line of products</td>
    </tr>
    <tr>
      <td>In     many cases, <font color="blue">third party</font> <font color="blue">manufacture</font>rs are not <font color="blue">obligated under contracts</font> that     fix the term of their <font color="blue">commitments</font>, and they <font color="blue">may <font color="blue">discontinue</font> production upon</font>     little or no advance notice</td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturers </font>also may experience <font color="blue">problems with</font>     product  quality  or  <font color="blue">timeliness</font> of <font color="blue">product delivery</font></td>
    </tr>
    <tr>
      <td>We rely on these     <font color="blue">manufacture</font>rs to <font color="blue">comply with applicable current</font> GMPs</td>
    </tr>
    <tr>
      <td>The loss of a contract     <font color="blue">manufacture</font>r may force us to shift production to in-house <font color="blue">facilities</font> and     possibly cause <font color="blue">manufacturing</font> delays, disrupt our ability to <font color="blue">fill orders</font> or     require  us  to  suspend  <font color="blue">production until</font> we find another <font color="blue">third party</font>     <font color="blue">manufacture</font>r</td>
    </tr>
    <tr>
      <td>We are not able to control the <font color="blue">manufacturing</font> efforts of these     <font color="blue">third party</font> <font color="blue">manufacture</font>rs as closely as we control our business</td>
    </tr>
    <tr>
      <td>Should any     of these <font color="blue">manufacture</font>rs fail to meet our standards, we may face <font color="blue">regulatory</font>     sanctions, <font color="blue">additional</font> <font color="blue">product <font color="blue">liability</font></font> claims or customer <font color="blue">complaints</font>, any     of which could harm our reputation and our business</td>
    </tr>
    <tr>
      <td>Our dietary supplement business <font color="blue">could suffer as</font> a result of injuries caused     by  dietary  <font color="blue">supplements</font> in general, <font color="blue">unfavorable scientific studies</font> or     <font color="blue">negative press</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">dietary <font color="blue">supplements</font></font> consist of <font color="blue">Dexatrim </font>and our Sunsource <font color="blue">product line</font></td>
    </tr>
    <tr>
      <td>We are highly <font color="blue">dependent upon</font> consumers’ perceptions of the benefit and     integrity of the <font color="blue">dietary <font color="blue">supplements</font></font> business as well as the safety and     quality of products in that industry</td>
    </tr>
    <tr>
      <td>Injuries caused by <font color="blue">dietary <font color="blue">supplements</font></font>     or <font color="blue">unfavorable scientific studies</font> or news relating to products in this     category, such as the <font color="blue">December </font>30, 2003 <font color="blue">consumer alert on</font> the safety of     <font color="blue"><font color="blue"><font color="blue">dietary <font color="blue">supplements</font></font> <font color="blue">containing ephedrine</font></font> <font color="blue">alkaloids</font></font> issued by the FDA and the     subsequent FDA <font color="blue">rule banning</font> the sale of <font color="blue">supplements</font> <font color="blue">containing ephedrine</font>     <font color="blue">alkaloids</font> that <font color="blue">became effective on</font> April 11, 2004, may <font color="blue">negatively affect</font>     consumers’ overall perceptions of products in this category, including our     products, which could harm the goodwill of these brands and cause our sales     to decline</td>
    </tr>
    <tr>
      <td>Our business could be <font color="blue"><font color="blue">adversely</font> affected</font> if we are unable to <font color="blue">successfully</font>     protect our <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">trademarks</font> are of material importance to our business and are among our     most  <font color="blue">important assets</font></td>
    </tr>
    <tr>
      <td>In fiscal 2005, substantially all of our total     revenues were <font color="blue"><font color="blue">from products</font> bearing <font color="blue">proprietary</font></font> or licensed brand names</td>
    </tr>
    <tr>
      <td>Accordingly,  our  <font color="blue">future success may depend</font> in part upon the goodwill     <font color="blue">associated with</font> our brand names, particularly Gold Bond, <font color="blue">Selsun Blue</font>, Icy     Hot  and Aspercreme</td>
    </tr>
    <tr>
      <td>Although our principal brand names are registered     <font color="blue">trademarks</font> in the <font color="blue">United States</font> and certain <font color="blue">foreign countries</font>, we cannot     assure you that the steps we take to protect our <font color="blue">proprietary</font> rights in our     brand  names will be adequate to prevent the <font color="blue">misappropriation</font> of these     registered brand names in the <font color="blue">United States</font> or abroad</td>
    </tr>
    <tr>
      <td>In addition, the laws     of some <font color="blue">foreign countries</font> do not protect <font color="blue">proprietary</font> rights in brand names     to the <font color="blue">same extent as</font> do the laws of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you     that  we  will  be  able  to  <font color="blue">successfully</font> protect our <font color="blue">trademarks</font> from     <font color="blue">infringement</font> or otherwise</td>
    </tr>
    <tr>
      <td>The loss or <font color="blue">infringement</font> of our <font color="blue">trademarks</font> could     impair the goodwill <font color="blue">associated with</font> our brands, harm our reputation and     <font color="blue">materially <font color="blue">adversely</font> affect</font> our financial results</td>
    </tr>
    <tr>
      <td>We license <font color="blue">additional</font> <font color="blue"><font color="blue">intellectual</font> property</font> from third parties that is used     in  certain of our products, and we <font color="blue">cannot assure</font> you that these third     parties can <font color="blue">successfully</font> maintain their <font color="blue"><font color="blue">intellectual</font> property</font> rights</td>
    </tr>
    <tr>
      <td>In     addition, the sale of these <font color="blue">products relies on</font> our ability to maintain and     extend our <font color="blue">licensing agreements</font> with third parties, and we <font color="blue">cannot assure</font> you     that we will be successful in maintaining these <font color="blue">licensing agreements</font></td>
    </tr>
    <tr>
      <td>Any     <font color="blue">significant</font>  <font color="blue">impairment</font>  of the <font color="blue"><font color="blue">intellectual</font> property</font> covered by these     licenses, or in our rights to use this <font color="blue"><font color="blue">intellectual</font> property</font>, may cause our     sales to decline</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">product line</font> <font color="blue">extensions</font> are <font color="blue">often based on new</font> or unique     <font color="blue">delivery methods</font> for those products like our Icy Hot patches and sleeves</td>
    </tr>
    <tr>
      <td>These <font color="blue">delivery methods</font> may not be protected by <font color="blue"><font color="blue">intellectual</font> property</font> rights     that we own or <font color="blue">license on</font>       22       _________________________________________________________________       an <font color="blue">exclusive basis</font> or by exclusive <font color="blue">manufacturing</font> agreements</td>
    </tr>
    <tr>
      <td>As a result, we     may be unable to prevent any <font color="blue">competitor</font> or customer from <font color="blue">duplicating</font> our     <font color="blue">delivery methods</font> to compete directly with these <font color="blue">product line</font> <font color="blue">extensions</font>,     which could cause sales to suffer</td>
    </tr>
    <tr>
      <td>We <font color="blue">may face litigation</font> in the future, either to protect our <font color="blue">intellectual</font>     <font color="blue">property rights</font> or to <font color="blue">defend against</font> claims that we have infringed the     <font color="blue"><font color="blue">intellectual</font> property</font> rights of others</td>
    </tr>
    <tr>
      <td><font color="blue">Intellectual </font><font color="blue">property litigation</font> can     be <font color="blue">extremely expensive</font>, and such expense could <font color="blue">materially <font color="blue">adversely</font> affect</font>     our business</td>
    </tr>
    <tr>
      <td>Because most of our <font color="blue">operations</font> are located in Chattanooga, Tennessee, we are     subject to regional and <font color="blue">local risks</font></td>
    </tr>
    <tr>
      <td><font color="blue">Approximately </font>60prca of our <font color="blue">sales volume</font> in fiscal 2005 was <font color="blue">from products</font>     <font color="blue">manufacture</font>d in <font color="blue">two plants located</font> in Chattanooga, Tennessee</td>
    </tr>
    <tr>
      <td>We store the     <font color="blue">raw materials used</font> in our <font color="blue">manufacturing</font> <font color="blue">activities</font> in <font color="blue">two warehouses</font> that     are <font color="blue">also located</font> in Chattanooga</td>
    </tr>
    <tr>
      <td>Additionally, our <font color="blue">corporate headquarters</font> are <font color="blue">also located</font>     in Chattanooga, and most of our employees live in the area</td>
    </tr>
    <tr>
      <td>Because of this,     we are subject to regional and <font color="blue">local risks</font>, such as:     •   changes in state and local <font color="blue">government</font> <font color="blue">regulations</font>;     •   severe weather <font color="blue">conditions</font>, such as floods, ice storms and tornadoes;     •   natural <font color="blue">disasters</font>, such as fires and <font color="blue">earthquakes</font>;     •   power outages;     •   nuclear <font color="blue">facility</font> <font color="blue">incidents</font>;     •   spread of <font color="blue">infectious</font> diseases;     •   <font color="blue">hazardous</font> material <font color="blue">incidents</font>; or     •   any other <font color="blue">catastrophic events</font> in our area</td>
    </tr>
    <tr>
      <td>If our region, city or <font color="blue">facilities</font> were to suffer a <font color="blue">significant</font> disaster, our     <font color="blue">operations</font> are likely to be disrupted and our business <font color="blue">would suffer</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on sole source suppliers</font> for <font color="blue">three active <font color="blue">ingredients</font> used</font> in our     Pamprin and Prēmsyn PMS products and a limited source of supply for selenium     sulfide, the active ingredient in <font color="blue">Selsun Blue</font>, and if we are unable to buy     these <font color="blue">ingredients</font>, we will not be able to <font color="blue">manufacture</font> these products</td>
    </tr>
    <tr>
      <td>Pamabrom, <font color="blue">pyrilamine maleate</font> and compap, active <font color="blue">ingredients</font> used in our     Pamprin and Prēmsyn PMS products, are <font color="blue">purchased from single sources</font> of     supply</td>
    </tr>
    <tr>
      <td><font color="blue">Pamabrom </font>is <font color="blue">sold only by</font> Chattem Chemicals, Inc</td>
    </tr>
    <tr>
      <td>(an unrelated     company), <font color="blue">pyrilamine maleate</font> is produced only in India and <font color="blue">sold only by</font>     Lonza, Inc</td>
    </tr>
    <tr>
      <td>and compap is <font color="blue">sold only by</font> Mallinckrodt, Inc</td>
    </tr>
    <tr>
      <td>In addition, we     have a limited source of supply for <font color="blue">selenium sulfide</font>, the active ingredient     in <font color="blue">Selsun Blue</font></td>
    </tr>
    <tr>
      <td>Financial, <font color="blue">regulatory</font> or other <font color="blue"><font color="blue">difficult</font>ies</font> faced by these     source  suppliers  or  <font color="blue">significant</font>  changes in demand for these active     <font color="blue">ingredients</font> could limit the <font color="blue">availability</font> and increase the price of these     active <font color="blue">ingredients</font></td>
    </tr>
    <tr>
      <td>We may not be able to obtain <font color="blue">necessary supplies</font> in a     <font color="blue">timely manner</font>, and we may be required to <font color="blue">pay higher than</font> expected prices for     these active <font color="blue">ingredients</font>, which could <font color="blue">adversely</font> affect our gross <font color="blue">margin from</font>     these products</td>
    </tr>
    <tr>
      <td>Any interruption or <font color="blue">significant</font> delay in the supply of these     active <font color="blue">ingredients</font> would impede our ability to <font color="blue">manufacture</font> these products,     <font color="blue">which would</font> cause our sales to decline</td>
    </tr>
    <tr>
      <td>We would not be able to find an     <font color="blue">alternative supplier</font> and <font color="blue">would either</font> need to <font color="blue">reformulate</font> these products or     <font color="blue">discontinue</font> their production</td>
    </tr>
    <tr>
      <td>While we do not currently know of any facts or     <font color="blue">circumstances</font> that would <font color="blue">adversely</font> affect the supply of pamabrom, pyrilamine     maleate, compap, or <font color="blue">selenium sulfide</font>, we <font color="blue">cannot assure</font> you that we will be     able to continue to <font color="blue">purchase adequate quantities</font> of these active <font color="blue">ingredients</font>     at acceptable prices in the future</td>
    </tr>
    <tr>
      <td>We are subject to the risk of doing business <font color="blue"><font color="blue">international</font>ly</font></td>
    </tr>
    <tr>
      <td>23       _________________________________________________________________       In fiscal 2005, <font color="blue">approximately</font> 10prca of our <font color="blue">total revenues</font> were <font color="blue">attributable</font> to     our <font color="blue">international</font> business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">acquisition</font> <font color="blue">of Selsun </font>Blue in 2002 has     greatly expanded our <font color="blue">international</font> business</td>
    </tr>
    <tr>
      <td>We operate in regions and     countries where we have little or no experience, and we may not be able to     market our products in, or develop new products <font color="blue">successfully</font> for, these     markets</td>
    </tr>
    <tr>
      <td>We <font color="blue">may also encounter</font> other risks of doing business <font color="blue"><font color="blue">international</font>ly</font>     including:     •   unexpected changes in, or <font color="blue">impositions</font> of, <font color="blue">legislative</font> or <font color="blue">regulatory</font>     <font color="blue">requirements</font>;     •   <font color="blue">fluctuations</font> in <font color="blue"><font color="blue">foreign exchange</font> rates</font>, which could cause <font color="blue">fluctuations</font>     in the price of our products in <font color="blue">foreign markets</font> or cause <font color="blue">fluctuations</font> in the     cost of <font color="blue">certain raw materials purchased by us</font>;     •   delays resulting from <font color="blue">difficult</font>y in obtaining export licenses, tariffs     and other barriers and restrictions, potentially longer payment cycles,     greater <font color="blue">difficult</font>y in <font color="blue">accounts receivable collection</font> and <font color="blue">potentially adverse</font>     <font color="blue">tax treatment</font>;     •   <font color="blue">potential trade restrictions</font> and <font color="blue">exchange controls</font>;     •   <font color="blue">differences</font> in protection of our <font color="blue"><font color="blue">intellectual</font> property</font> rights; and     •   the burden of <font color="blue">complying with</font> a variety of <font color="blue">foreign laws</font></td>
    </tr>
    <tr>
      <td>In addition, we will be <font color="blue">increasingly</font> subject to <font color="blue">general geopolitical risks</font>     in  foreign  countries where we operate <font color="blue">such as political</font> and economic     <font color="blue">instability</font> and changes in diplomatic and trade <font color="blue">relationships</font>, which could     affect,  among  other things, customers’ inventory levels and consumer     purchasing, which could cause our results to fluctuate and our sales to     decline</td>
    </tr>
    <tr>
      <td>It has not been our practice to engage in <font color="blue"><font color="blue">foreign exchange</font> hedging</font>     <font color="blue"><font color="blue">transaction</font>s</font> to manage the risk of <font color="blue">fluctuations</font> in <font color="blue"><font color="blue">foreign exchange</font> rates</font>     because of the limited nature of our past <font color="blue">international</font> <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Due to     the <font color="blue">significant</font> expansion of our <font color="blue">international</font> <font color="blue">operations</font> as a result of the     <font color="blue"><font color="blue">Selsun Blue</font> </font><font color="blue">acquisition</font>, our exposure to <font color="blue">fluctuations</font> in <font color="blue">foreign exchange</font>     rates has increased</td>
    </tr>
    <tr>
      <td>We  have  a <font color="blue">significant</font> amount of debt that could <font color="blue">adversely</font> affect our     business and <font color="blue">growth prospects</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of November </font>30, 2005, our total long-term debt was dlra182dtta5 million</td>
    </tr>
    <tr>
      <td>In the     future  we  may incur <font color="blue">significant</font> <font color="blue">additional</font> debt</td>
    </tr>
    <tr>
      <td>Our <font color="blue">debt could</font> have     <font color="blue">significant</font> adverse effects on our business including:     •   requiring us to dedicate a substantial portion of our <font color="blue">available cash</font> for     <font color="blue">interest payments</font> and the repayment of principal;     •    limiting  our  ability  to  <font color="blue">capitalize</font>  on  <font color="blue">significant</font>  business     <font color="blue">opportunities</font>;     •   making us more vulnerable to <font color="blue">economic downturns</font>;     •   limiting our ability to withstand <font color="blue">competitive</font> pressures; and     •    making it more <font color="blue">difficult</font> for us to obtain <font color="blue">additional</font> financing on     favorable terms</td>
    </tr>
    <tr>
      <td>If we are unable to generate sufficient cash flow from <font color="blue">operations</font> in the     future, we may not be able to service our debt and may have to refinance all     or a portion of our debt, obtain <font color="blue">additional</font> financing or <font color="blue">sell assets</font> to     <font color="blue">repay such debt</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will be able to obtain such     refinancing, <font color="blue">additional</font> financing or <font color="blue">asset sale on</font> favorable terms or at     all</td>
    </tr>
    <tr>
      <td>The  terms  of  our  <font color="blue">outstanding debt obligations limit certain</font> of our     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>The terms of the <font color="blue">indenture under which</font> our 7dtta0prca <font color="blue">Subordinated Notes </font>are     issued  and our <font color="blue">Amended Revolving Credit Facility </font>impose operating and     <font color="blue">financial <font color="blue">restrictions on</font> us</font> including <font color="blue">restrictions on</font>:     •   incurrence of <font color="blue"><font color="blue">additional</font> <font color="blue">indebtedness</font></font>;     •   dividends and <font color="blue">restricted payments</font>;     •   <font color="blue">investments</font>;     •   loans and <font color="blue">guarantees</font>;     24       _________________________________________________________________       •   creation of liens;     •   <font color="blue"><font color="blue">transaction</font>s</font> with affiliates;     •   use of <font color="blue">proceeds from sales</font> of assets and <font color="blue">subsidiary stock</font>; and     •   certain mergers, <font color="blue">consolidation</font>s and transfers of assets</td>
    </tr>
    <tr>
      <td>The terms of our <font color="blue">Amended Revolving Credit Facility </font>also require us to comply     <font color="blue">with financial maintenance covenants</font></td>
    </tr>
    <tr>
      <td>In the future, we may have other     <font color="blue">indebtedness</font>  with  similar  or even more <font color="blue">restrictive</font> covenants</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">restrictions may impair</font> our ability to respond to changing business and     economic <font color="blue">conditions</font> or to grow our business</td>
    </tr>
    <tr>
      <td>In the event that we fail to     comply with these covenants, there could be an event of default under the     applicable debt instrument, which in turn could cause a cross default to     other debt <font color="blue">instruments</font></td>
    </tr>
    <tr>
      <td>As a result, all amounts outstanding under our     various debt <font color="blue">instruments</font> may become <font color="blue">immediately</font> due and payable</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">operations</font>  are  subject  to  <font color="blue">significant</font>  <font color="blue"><font color="blue">environmental</font> laws</font> and     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">manufacturing</font> sites use chemicals and other potentially <font color="blue">hazardous</font>     materials  and  generate  both  <font color="blue">hazardous</font> and non-<font color="blue">hazardous</font> waste, the     transportation, treatment, storage and disposal of which are <font color="blue">regulated by</font>     various <font color="blue"><font color="blue">government</font>al</font> agencies and federal, state and <font color="blue">local laws</font></td>
    </tr>
    <tr>
      <td>Under these     laws, we are exposed to <font color="blue">liability</font> primarily as an owner or operator of real     property, and as such, we may be responsible for the clean-up or other     <font color="blue">remediation</font> of <font color="blue">contaminated property</font></td>
    </tr>
    <tr>
      <td><font color="blue">Environmental </font>laws and <font color="blue">regulations</font> can     change rapidly, and we may become subject to more <font color="blue">stringent <font color="blue">environmental</font></font>     laws and <font color="blue">regulations</font> in the future, which may be <font color="blue">retroactively applied</font> to     <font color="blue">earlier events</font></td>
    </tr>
    <tr>
      <td>Product line <font color="blue">extensions</font>, such as Bullfrog Mosquito Coast, or     <font color="blue">acquisition</font>s  of  new products may also subject our business to new or     <font color="blue">additional</font> <font color="blue"><font color="blue">environmental</font> laws</font> and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>In addition, compliance with     new or more stringent <font color="blue"><font color="blue">environmental</font> laws</font> and <font color="blue">regulations</font> could involve     <font color="blue">significant</font> costs</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent on certain key executives</font>, the loss of whom could have a     material adverse effect on our business</td>
    </tr>
    <tr>
      <td>Our future performance depends <font color="blue">significant</font>ly upon the efforts and <font color="blue">abilities</font>     of <font color="blue">certain members</font> of <font color="blue">senior management</font>, in particular those of Zan Guerry,     our  chairman and chief executive officer, and Robert E Bosworth, our     president and chief operating officer</td>
    </tr>
    <tr>
      <td>If we were to lose any key senior     executive, our business could be <font color="blue">materially <font color="blue">adversely</font> affect</font>ed</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">shareholder</font> rights</font> plan and <font color="blue"><font color="blue">restated charter</font> contain provisions</font> that may     delay or prevent a merger, tender offer or other change of control of us</td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of our <font color="blue"><font color="blue">shareholder</font> rights</font> plan and our <font color="blue">restated charter</font>, as well     as certain provisions <font color="blue">of Tennessee </font>corporation law, may deter unfriendly     offers  or  other  efforts to obtain <font color="blue">control over us</font> and <font color="blue">could deprive</font>     <font color="blue">shareholder</font>s of their ability to receive a <font color="blue">premium on</font> their <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Generally, if any person attempts to acquire 15prca or more of our <font color="blue">common stock</font>     then outstanding without the approval of our <font color="blue">independent</font> <font color="blue">directors</font>, pursuant     to our <font color="blue"><font color="blue">shareholder</font> rights</font> plan, our <font color="blue">shareholder</font>s may purchase a <font color="blue">significant</font>     amount  of  <font color="blue">additional</font>  shares  of our <font color="blue">common stock</font> at 50prca of the then     <font color="blue">applicable market price</font></td>
    </tr>
    <tr>
      <td>This threat of substantial <font color="blue">dilution will discourage</font>     <font color="blue">takeover attempts</font> not <font color="blue">approved by</font> our board despite <font color="blue">significant</font> potential     benefits to our <font color="blue">shareholder</font>s</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">restated charter</font> contains</font> the following <font color="blue">additional</font> provisions, which may     have the effect of discouraging <font color="blue">takeover attempts</font>:                                         •       our <font color="blue">directors</font> are divided into three classes, with only one class of     <font color="blue">directors</font> elected at each annual meeting for a term of <font color="blue">three years</font>, making     it <font color="blue">difficult</font> for new <font color="blue">shareholder</font>s to <font color="blue">quickly gain control</font> of our board of     <font color="blue">directors</font>;                                         •       <font color="blue">directors</font> may be <font color="blue">removed only</font> for cause prior to the expiration of their     terms; and                                         •       we are <font color="blue">prohibited from</font> engaging in certain business <font color="blue">combination</font> <font color="blue"><font color="blue">transaction</font>s</font>     with any interested <font color="blue">shareholder</font> unless such <font color="blue">transaction</font> is <font color="blue">approved by</font> the     <font color="blue">affirmative vote</font> of at least 80prca of the <font color="blue">outstanding shares</font> of our common     stock held by disinterested <font color="blue">shareholder</font>s, unless <font color="blue">disinterested members</font> of     our board of <font color="blue">directors</font> approve the <font color="blue">transaction</font> or <font color="blue">certain fairness</font>     <font color="blue">conditions</font> are satisfied, in which case such <font color="blue">transaction</font> may be <font color="blue">approved by</font>     either the <font color="blue">affirmative vote</font> of the holders of not less than 75prca of our     <font color="blue">outstanding shares</font> of <font color="blue">common stock</font> and the <font color="blue">affirmative vote</font> of the       25       _________________________________________________________________         holders of not less than 66prca of the <font color="blue">outstanding shares</font> of our <font color="blue">common stock</font>     which are not owned by the interested <font color="blue">shareholder</font>, or by a majority of     <font color="blue">disinterested members</font> of our board of <font color="blue">directors</font>, provided that certain     quorum <font color="blue">requirements</font> are met</td>
    </tr>
    <tr>
      <td><font color="blue">The Tennessee Business Combination Act </font>prevents an interested <font color="blue">shareholder</font>,     which is defined <font color="blue">generally</font> as a person owning 10prca or more of our voting     stock,  from engaging in a business <font color="blue">combination</font> with us for <font color="blue">five years</font>     following the date such person became an interested <font color="blue">shareholder</font> unless     before such person became an interested <font color="blue">shareholder</font>, our board of <font color="blue">directors</font>     approved the <font color="blue">transaction</font> in which the interested <font color="blue">shareholder</font> became an     interested  <font color="blue">shareholder</font>  or approved the business <font color="blue">combination</font>, and the     proposed  business  <font color="blue">combination</font>  satisfied  any  <font color="blue">additional</font> applicable     <font color="blue">requirements</font> imposed by law and by our <font color="blue">restated charter</font> or bylaws</td>
    </tr>
    <tr>
      <td>If the     requisite approval for the business <font color="blue">combination</font> or share <font color="blue">acquisition</font> has not     been obtained, any business <font color="blue">combination</font> is <font color="blue">prohibited until</font> the expiration     of  five  years  following  the  date such person became an interested     <font color="blue">shareholder</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">trading price</font> of our <font color="blue">common stock</font> may be volatile</td>
    </tr>
    <tr>
      <td>The  <font color="blue">trading price</font> of our <font color="blue">common stock</font> could be subject to <font color="blue">significant</font>     <font color="blue">fluctuations</font> in response to <font color="blue">several factors</font>, some of which are beyond our     control,  including <font color="blue">variations</font> in our quarterly operating results, our     leveraged financial position, potential sales of <font color="blue">additional</font> shares of our     <font color="blue">common stock</font>, general trends in the <font color="blue">consumer products</font> industry, changes by     <font color="blue">securities analysts</font> in their estimates or <font color="blue">investment ratings</font>, the relative     <font color="blue">illiquidity</font>  of  our  <font color="blue">common stock</font>, news regarding PPA-related product     <font color="blue">liability</font> litigation and other potential <font color="blue">product <font color="blue">liability</font></font> litigation and     stock market <font color="blue">conditions</font> <font color="blue">generally</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">no current intention</font> of <font color="blue">paying dividends</font> to holders of our common     stock</td>
    </tr>
    <tr>
      <td>We  presently  intend  to  retain our earnings, if any, for use in our     <font color="blue">operations</font>, to repurchase our <font color="blue">common stock</font> and to repay our outstanding     <font color="blue">indebtedness</font> and have <font color="blue">no current intention</font> of <font color="blue">paying dividends</font> to holders of     our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Market Data     We use market and industry data throughout this <font color="blue">Annual Report </font>on Form 10-K     and the documents incorporated by reference herein, which we have obtained     from  market  research,  publicly  available  information and industry     <font color="blue">publications</font></td>
    </tr>
    <tr>
      <td>These sources <font color="blue">generally</font> state that the information that they     provide has been obtained <font color="blue">from sources</font> believed to be reliable, but that the     accuracy and <font color="blue">completeness</font> of such information are not guaranteed</td>
    </tr>
    <tr>
      <td>The market     and industry data is <font color="blue">often based on industry surveys</font> and the preparers’     experience in the industry</td>
    </tr>
    <tr>
      <td>Similarly, although we believe that the surveys     and <font color="blue">market research</font> that others have performed are reliable, we have not     <font color="blue"><font color="blue">independent</font>ly</font>  verified  this information</td>
    </tr>
    <tr>
      <td>In particular, market share     information has <font color="blue">been coordinated</font> and prepared for us by AC Nielsen at our     <font color="blue">request based on market segments</font> that we defined and for which we have paid     customary  fees</td>
    </tr>
    <tr>
      <td>Therefore,  such data, including the market category     <font color="blue">delineations</font>  that  form  the basis for such data, are not <font color="blue">necessarily</font>     <font color="blue">representative</font> of results that would have been obtained from an <font color="blue">independent</font>     source</td>
    </tr>
  </tbody>
</table>